nivolumab

  • August 5, 2022  

    FDA Approves Two Nivolumab-Based Regimens as First-Line Treatments for Unresectable Advanced or Metastatic Esophageal Squamous Cell Carcinoma Bookmark

    George Lundberg, MD

    The ASCO Post reports on the U.S. Food And Drug Administration (FDA)’s recent approval of two new treatments for advanced, unresectable squamous cell carcinoma of the esophagus.

    .

  • August 5, 2022  

    Good for Bladder Cancer, Better for Kidney Cancer Bookmark

    George Lundberg, MD

    This article from the National Cancer Institute’s Center for Cancer Research outlines new clinical trial results showing that combining the drugs cabozantinib and nivolumab doubled progression-free survival for people with advanced renal cell carcinoma compared to giving cabozantinib alone.

    .

  • July 30, 2022  

    Relatlimab and Nivolumab vs Nivolumab in Previously Untreated Metastatic/Unresectable Melanoma: Overall Survival and Response From RELATIVITY-047 Bookmark

    George Lundberg, MD

    According to MedPage Today, the addition of the drug relatlimab to treatment with nivolumab improved survival for people with advanced melanoma in a clinical trial.

    .

  • March 8, 2022  

    Immunotherapy Before Targeted Therapy Extends OS in Metastatic Melanoma Bookmark

    George Lundberg, MD

    As reported by Healio, immunotherapy followed by targeted therapy improved overall survival in a clinical trial with metastatic melanoma patients.

    .

  • July 28, 2021  

    2021 ASCO Annual Meeting Bookmark

    George Lundberg, MD

    Researchers at the 2021 annual meeting of the American Society of Clinical Oncology (ASCO) reported substantial advances in treatment for advanced esophageal, castration-resistant prostate, and metastatic nasopharyngeal cancers.

    .

  • July 14, 2021  

    What’s New in Melanoma Treatment in 2021?

    Emma Shtivelman, PhD

    I last wrote about melanoma treatment more than 2 years ago, a fairly long time in the evolution of treatments for this type of cancer. Just as a refresher, the current mainstays of drugs to treat melanoma fall into two categories: Now, I highlight new developments in melanoma treatment, including overcoming resistance to ICI. Neoadjuvant (before surgery) treatments for resectable melanoma Some stage III… Read more »

  • April 12, 2021  

    Nivolumab: First Adjuvant Immunotherapy to Show Survival Benefit in High-Risk Muscle-Invasive Urothelial Cancer Bookmark

    George Lundberg, MD

    The ASCO Post reports new results from a clinical trial in which the drug nivolumab (Opdivo) nearly doubled progression-free survival compared to a placebo drug for people with muscle-invasive bladder cancer.

    .

  • April 12, 2021  

    Adjuvant Nivolumab in Resected Esophageal or Gastroesophageal Junction Cancer Bookmark

    George Lundberg, MD

    An academic research paper published in The New England Journal of Medicine reports new results from a phase III, randomized, double-blinded, controlled clinical trial. In the trial, people with esophageal or gastroesophageal junction cancer that had been surgically resected were treated with either a placebo drug or the drug nivolumab. All patients had previously received chemotherapy before resection and had residual disease after surgery. The findings suggest that nivolumab may be beneficial, as median disease-free survival in was doubled (22 versus 11 months) in the nivolumab treated group compared to the placebo group.

    .

  • December 3, 2020  

    Opdivo Approved in Europe as Second-line Therapy for Advanced Esophageal Cancer Bookmark

    George Lundberg, MD

    Immuno-Oncology News reports on the European Commission’s approval of the drug nivolumab (Opdivo) for some patients with advanced esophageal cancer.

    .

  • November 24, 2020  

    For Esophageal Cancer, Immunotherapy Likely to Play Larger Role Bookmark

    George Lundberg, MD

    A blog post from the National Cancer Institute reports that two clinical trials are showing encouraging results for progression-free survival—and one for overall survival—from treatment with immunotherapy drugs in people with advanced esophageal cancer. 

    .